NX Prenatal to present innovative technology on preterm birth at Philadelphia Prenatal Conference

GRAND RAPIDS, Mich., May 31, 2017 /PRNewswire/ -- NxGen MDx announced that it is sponsoring the presentation of NX Prenatal's innovative technology at the ninth Philadelphia Prenatal Conference in Philadelphia, Pennsylvania.

The Philadelphia Prenatal Conference, held from June 8-10, will focus on prenatal genetics, ultrasound, and obstetrics/maternal-fetal medicine, with presentations from leading experts in the field.

NX Prenatal is focused on the development of an exosome-based blood test designed to predict the risk of spontaneous preterm birth as early as 10-12 weeks of pregnancy. This test, the NeXosome Preterm Birth Risk Assay, uses exosomes from the maternal bloodstream to provide an accurate, non-invasive view of maternal and fetal cells and tissues. Dr. Thomas McElrath, who has served as Principle Investigator for NX Prenatal's recent clinical studies, will present to the group. Dr. McElrath is Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and an attending physician at Brigham & Women's Hospital where he specializes in Maternal & Fetal Medicine with a focus on the prevention of spontaneous preterm birth. Dr. McElrath manages the Preterm Birth Clinic at Brigham and Women's Hospital. He actively publishes on the biomarker epidemiology and classification of preterm birth and the interaction of environmental conditions and exposures with the risk of preterm birth.

"Preterm birth is a huge problem in the U.S. with one in ten births being premature. Our goal is to raise awareness of this problem and through this novel approach, be part of the solution in identifying the risk of preterm birth," said Alan Mack, CEO of NxGen MDx.

About NX Prenatal
NX Prenatal Inc. is a private, US-based molecular diagnostics company. The company's NeXosome® Preterm Birth Risk Assay is positioned to be an enabling, early warning system for pregnancies that may result in spontaneous preterm birth. Using its proprietary NeXosome Platform, NX Prenatal has demonstrated the potential utility of a new library of biomarkers for prenatal risk assessment as early as 10 weeks' gestation. This technology exploits biologically active and stable microparticles, such as exosomes, from the maternal bloodstream, to provide a real-time and non-invasive view of changing maternal and fetal cells and tissues.

About NxGen MDx
NxGen MDx LLC is a leading women's health company delivering highly accurate and precise genetic screening to detect genetic diseases or abnormalities to help guide family planning decisions for couples and their health care providers. Unlike other laboratories, NxGen MDx's technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. NxGen MDx is located in Grand Rapids, Michigan. To learn more, visit the company's website at www.nxgenmdx.com.

SOURCE NxGen MDx